| |
| | Patent 7,138,431 |
 | | As an additional element, the increase in arachidonic acid that is normally seen in serum fatty acids with administration of GLA may be inhibited by administering a.DELTA..sup.5 desaturase inhibitor, such as eicosapentaenoic acid (EPA), for example. |
 | | These acids may form part of a phospholipid, steryl ester, a sphingolipid, a glyceride, such as a di- or triglyceride or may be present as free fatty acids. |
 | | Pharmaceutically acceptable salts, include the acid addition salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. |
| www.pharmcast.com /Patents100/Yr2006/Nov2006/112106/7138431_Arachidonic112106.htm (4982 words) |
|